A double-blind study on clonazepam in patients with burning mouth syndrome

作者：Heckmann Siegfried M; Kirchner Elena; Grushka Miriam; Wichmann Manfred G; Hummel Thomas^*

来源：Laryngoscope, 2012, 122(4): 813-816.

DOI：10.1002/lary.22490

• Pain
• taste
• glossodynia
• treatment
• irritation
• hypogeusia
• Level of Evidence: 1b

Objectives/Hypothesis: In the treatment of burning mouth syndrome (BMS), various approaches have been tried with equivocal results. The aim of the present randomized clinical trial was to determine the efficacy of clonazepam, a GABA agonist designed as an antiepileptic drug that exerts the typical effects of benzodiazepines. %26lt;br%26gt;Study Design: Randomized clinical trial. %26lt;br%26gt;Methods: Twenty patients with idiopathic BMS were carefully selected. Clonazepam (0.5 mg/ day, n 10) or placebo (lactose, n 10) were randomly assigned to the patients. %26lt;br%26gt;Results: Patients on clonazepam significantly improved in pain ratings (P %26lt;.001). These changes were less pronounced in the placebo group (P %26lt;.11). No significant changes were observed in a mood scale (P.56) or for depression scores (P.56). Taste test and salivary flow increased over sessions, but were not different between groups (P.83 and P.06, respectively). %26lt;br%26gt;Conclusions: Clonazepam appears to have a positive effect on pain in BMS patients.

• 出版日期2012-4